Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Explore this paper's citation graph
Summary
Overall safety and activity of liso-cel did not differ by dose level, with a high objective response rate, and a low incidence of grade 3 or worse cytokine release syndrome and neurological events in patients with relapsed or refractory large B-cell lymphomas.
- Type
- article
- Published
- 2020-09-01
- Cited by
- 1,982
- References
- 38
- OpenAlex
- https://openalex.org/W3082855561
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:221400411
Keywords
Refractory (planetary science), Medicine, Internal medicine, Oncology, Lymphoma
References
- How I treat elderly patients with diffuse large B-cell lymphoma.
- Current concepts in the diagnosis and management of cytokine release syndrome.
- Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
- Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
- A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient population.
- Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
- Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
- Event-Free Survival at 24 Months Captures Central Nervous System Relapse of Systemic Diffuse Large B-cell Lymphoma in the Immunochemotherapy Era
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- JCAR017 Is a Defined Composition CAR T Cell Product with Product and Process Controls That Deliver Precise Doses of CD4 and CD8 CAR T Cell to Patients with NHL
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
- Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.
- Overall survival (OS) and transplantation (ASCT) utilization in real-world patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL).
- Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Cited by
- Diffuse large B-cell lymphoma
- Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1
- Initial results with liso-cel
- Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy
- CAR T-cell Therapy Hopes to Move to Second Line in Diffuse Large B-cell Lymphoma
- Chimeric Antigen Receptor T-Cell Therapy
- Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
- Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy – what are we doing; where are we going?
- Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin’s lymphoma: the survival gain improves as more mature follow-up data become available
- C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas.
- CART Cell Toxicities: New Insight into Mechanisms and Management
- Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)
- Immunotherapy with cells.
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma: Is It Time to Consider CAR-T for All?
- The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome
- Regulating innovation in the early development of cell therapies
- Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration.
- CAR T cells better than BiTEs.
- CART Cells: A New Dawn in Cancer Immunotherapy
- Recent advances in cellular therapy for malignant lymphoma.
Related papers
- DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION
- Genentech taps Affimed’s antibodies
- KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria
- Cardiac retransplantation in children.
- Avaliacao hemodinamica sequencial em transplante de coracao
- Thoracoscopic discectomy and fusion in the treatment of spinal deformities
- [Hepatic retransplant and acute Budd Chiari syndrome. Case report].